[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Haematology](https://durgical.com/en/haematology/) › [White cells and leukaemia](https://durgical.com/en/haematology/areas/white-cells/) › Supportive care in blood cancers

# Supportive care in blood cancers

- Treatment and support

Many people with blood cancer die of infection, bleeding or side effects rather than the cancer. Good support is what lets the curative treatment work.

Updated Nov 15, 2026

## Key points

- The regimen predicts the problems: neutropenia → bacteria and moulds; lymphocyte-killing drugs and steroids → viruses and [Pneumocystis](https://durgical.com/en/microbiology/pneumocystis-jirovecii/).
- Hepatitis B screening before anti-CD20 and transplant.
- Irradiated products for Hodgkin, purine analogues and transplant.
- [Fertility preservation](https://durgical.com/en/obstetrics-gynaecology/fertility-preservation/) is offered before treatment starts.
- Prophylaxis never replaces antibiotics for neutropenic fever.

On this page

- The basics Key points
- What it is
- How to think about it
- What to know
- How it is done (and why)
- Which prophylaxis for which risk
- Common traps
- Elsewhere in DurgiPedia

- Safety Risks and precautions
- Monitoring and next step

- Study Test yourself

- Connections Connections

## What it is

Supportive care is everything that keeps a patient safe while the marrow is empty and the immune system is down: preventing and treating infection, transfusing blood products safely, preventing [tumour lysis](https://durgical.com/en/conditions/tumour-lysis-syndrome/), controlling nausea and mucositis, protecting fertility, nutrition and the central line, and palliative and psychological care from the start. It is planned before treatment begins, because the drug classes and the expected length of neutropenia predict which problems will come.

## How to think about it

Treat supportive care as a forecast: the regimen tells you the weather. Long, deep neutropenia (AML induction, transplant) brings bacterial and mould storms; lymphocyte-killing drugs and steroids (purine analogues, ALL protocols, anti-CD20, [proteasome](https://durgical.com/en/biochemistry/enzymes/proteasome/) inhibitors) bring viral and Pneumocystis weather; bulky fast tumours bring tumour lysis. Read the regimen, then put up the right shelter before it rains.

## What to know

- Bacterial prophylaxis with a fluoroquinolone is used in expected long, deep neutropenia; a fever still needs immediate empirical antibiotics.
- Antifungal prophylaxis with a mould-active azole is used in AML and high-risk MDS induction and in [graft-versus-host disease](https://durgical.com/en/conditions/graft-versus-host-disease/); azoles interact with many drugs, including [vincristine](https://durgical.com/en/pharmacology/vincristine/) and [venetoclax](https://durgical.com/en/pharmacology/venetoclax/).
- Antiviral prophylaxis against herpes simplex and [zoster](https://durgical.com/en/conditions/herpes-zoster/) with [aciclovir](https://durgical.com/en/pharmacology/aciclovir/) or [valaciclovir](https://durgical.com/en/pharmacology/valaciclovir/) is used with proteasome inhibitors, purine analogues, anti-CD38 [antibodies](https://durgical.com/en/biochemistry/enzymes/immunoglobulins/) and transplant.
- Pneumocystis prophylaxis is used in ALL, with prolonged steroids, purine analogues and after transplant.
- Hepatitis B screening before anti-CD20 antibodies and transplant, with antiviral prophylaxis in carriers or past infection; inactivated vaccines only, no live vaccines during treatment.
- Irradiated cellular blood products prevent transfusion-associated graft-versus-host disease in [Hodgkin lymphoma](https://durgical.com/en/conditions/hodgkin-lymphoma/), after purine analogues and around stem cell transplant.

## How it is done (and why)

- Before treatment: assess the regimen, expected neutropenia, comorbidities, dental health and the venous access needed.
- Screen for hepatitis B, hepatitis C, HIV and latent infections such as Strongyloides or [tuberculosis](https://durgical.com/en/conditions/tuberculosis/) where relevant.
- Offer fertility preservation (sperm or egg storage, ovarian protection) before gonadotoxic treatment.
- Plan tumour lysis prevention, antiemetics matched to the regimen's emetic risk, and infection prophylaxis.
- Agree on transfusion thresholds and special product needs (irradiated, CMV-safe) and alert the blood bank.
- During treatment: daily review for fever, mucositis, bleeding, nutrition, line problems and mood.
- Bring [palliative care](https://durgical.com/en/anaesthesia/palliative-care-what-it-is-and-when-it-starts/) in early for symptom control alongside curative treatment, not only at the end.

## Which prophylaxis for which risk

| Risk | When it applies | Prevention principle | Watch for |
| --- | --- | --- | --- |
| Bacteria | Long, deep neutropenia (AML induction, transplant) | Fluoroquinolone prophylaxis; [hand hygiene](https://durgical.com/en/nursing/hand-hygiene-the-five-moments-and-the-technique/); line care | Resistance, [Clostridioides difficile](https://durgical.com/en/microbiology/clostridioides-difficile/), QT prolongation |
| Moulds and yeasts | AML/MDS induction, graft-versus-host disease | Mould-active azole | [Liver](https://durgical.com/en/anatomy/liver/) tests, [drug interactions](https://durgical.com/en/pharmacology/topics/drug-interactions/) (vincristine, venetoclax) |
| Herpes viruses | Proteasome inhibitors, purine analogues, anti-CD38, transplant | Aciclovir or valaciclovir | Kidney function; CMV monitoring after allogeneic transplant |
| Pneumocystis | ALL, long steroid courses, purine analogues, transplant | Co-trimoxazole or an alternative | Low counts, rash, [high potassium](https://durgical.com/en/conditions/hyperkalaemia/) |
| Hepatitis B reactivation | Anti-CD20 antibodies, transplant, intensive chemotherapy | Screen all; antiviral prophylaxis in carriers or past infection | Rising liver enzymes and HBV DNA |
| Transfusion GVHD | Hodgkin lymphoma, purine analogues, transplant | Irradiated cellular products | Product label at every transfusion |

## Risks and precautions

- Fever in a neutropenic patient is treated within the first hour regardless of prophylaxis; prophylaxis lowers the risk, it does not exclude infection.
- [Azole antifungals](https://durgical.com/en/pharmacology/classes/azole-antifungals/) raise the levels of vincristine (neuropathy, ileus) and venetoclax (tumour lysis, low counts), so every new drug is checked for interactions.
- Thrombocytopenic women of reproductive age need a plan to suppress menstruation during intensive treatment.
- Mucositis is prevented with oral care and treated with pain control and nutrition; severe mucositis is a portal for bacteria into the blood.
- In Colombia, Ley 1733 de 2014 gives patients with serious illness the right to palliative care, and [Ley 1388](https://durgical.com/en/pediatrics/warning-signs-of-childhood-cancer-and-the-colombian-route/) de 2010 protects prompt, comprehensive care for children with cancer.

## Monitoring and next step

- Before treatment: full count, kidney and liver tests, [uric acid](https://durgical.com/en/biochemistry/molecules/uric-acid/), hepatitis B surface antigen and core antibody, hepatitis C, HIV, and group and screen.
- During neutropenia: daily count and chemistry; blood cultures from every line lumen and a peripheral vein with any fever.
- Mould risk: galactomannan or chest CT when fever persists despite antibiotics.
- After allogeneic transplant: regular CMV DNA monitoring to guide pre-emptive treatment.
- Hepatitis B carriers on prophylaxis: liver enzymes and HBV DNA during and after treatment.

## Common traps

- **Relaxing about a fever because the patient is on prophylaxis**: prophylaxis lowers the risk but every neutropenic fever still needs empirical antibiotics within the hour
- **Starting an azole antifungal without checking the chemotherapy**: azoles raise vincristine and venetoclax levels and cause serious toxicity
- **Skipping hepatitis B screening before anti-CD20 therapy**: reactivation can cause fatal liver failure and is preventable
- **Giving non-irradiated blood after purine analogues or in Hodgkin lymphoma**: transfusion-associated GVHD is almost always fatal
- **Calling palliative care only when cure is no longer possible**: early symptom care improves quality of life during curative treatment

## Test yourself

Think of the answer, then tap the question to see it.

## A 40-year-old starting AML induction is prescribed a mould-active azole and, two days later, vincristine is proposed for a different diagnosis. What problem should you anticipate?

Azoles block the liver enzyme that clears vincristine, raising its levels and causing severe neuropathy and ileus; the combination is avoided or the plan changed.

## A man with lymphoma is about to receive an anti-CD20 antibody. He is HBsAg negative but anti-HBc positive. What is the next step?

Antiviral prophylaxis or close HBV DNA monitoring, because past infection can reactivate under B-cell depletion and cause severe hepatitis.

## Why are irradiated red cells and platelets needed after treatment with a purine analogue such as fludarabine?

The drug leaves a lasting T-cell deficit, so donor lymphocytes in the product can engraft and attack the recipient (transfusion-associated GVHD); irradiation stops them dividing.

## A young woman is about to start chemotherapy for Hodgkin lymphoma. Which supportive step must be offered before the first cycle?

Fertility counselling and preservation, because the chance to store eggs or embryos is lost once gonadotoxic treatment begins.

[Add to my cards (4)](https://durgical.app/estudiar/?add=/en/haematology/supportive-care-in-blood-cancers/)

## Elsewhere in DurgiPedia

- [The neutropenic and immunosuppressed patient (nursing)](https://durgical.com/en/immunology/the-neutropenic-and-immunosuppressed-patient/)
- [Side effects of cancer treatment: nausea, mucositis, hair loss, fatigue and appetite](https://durgical.com/en/nursing/side-effects-of-cancer-treatment-nausea-mucositis-hair-loss-fatigue-and-appetite/)
- [The child with cancer: neutropenic precautions, mucositis, nausea, the central line and the family](https://durgical.com/en/nursing/the-child-with-cancer-neutropenic-precautions-mucositis-nausea-the-central-line/)
- [The mouth during cancer treatment: mucositis, dry mouth and osteonecrosis](https://durgical.com/en/dentistry/the-mouth-during-cancer-treatment-mucositis-dry-mouth-and-osteonecrosis/)
- [Complications of transfusion](https://durgical.com/en/general-pathology/complications-of-transfusion/)
- [Ley 1733 de 2014: palliative care](https://durgical.com/en/medical-ethics/ley-1733-de-2014-palliative-care/)
- [Live vaccines: who should not receive them](https://durgical.com/en/immunology/live-vaccines-who-should-not-receive-them/)

## Connections

## Related 7

- [Fever with low neutrophils: the first hour](https://durgical.com/en/haematology/fever-with-low-neutrophils-the-first-hour/)
- [Tumour lysis syndrome: prevent, recognise, treat](https://durgical.com/en/haematology/tumour-lysis-syndrome-prevent-recognise-treat/)
- [Blood components: red cells, platelets, plasma and cryoprecipitate, and when each is used](https://durgical.com/en/haematology/blood-components-red-cells-platelets-plasma-and-cryoprecipitate-and-when-each-is/)
- [Toxicities of blood-cancer treatment by drug class](https://durgical.com/en/haematology/toxicities-of-blood-cancer-treatment-by-drug-class/)
- [Growth factors and marrow stimulants: G-CSF, ESAs, TPO receptor agonists](https://durgical.com/en/haematology/growth-factors-and-marrow-stimulants-g-csf-esas-tpo-receptor-agonists/)
- [How leukaemia is treated: induction, consolidation, targeted drugs and support](https://durgical.com/en/haematology/how-leukaemia-is-treated-induction-consolidation-targeted-drugs-and-support/)
- [Stem cell transplantation: autologous or allogeneic, and what can go wrong](https://durgical.com/en/haematology/stem-cell-transplantation-autologous-or-allogeneic-and-what-can-go-wrong/)

## Related conditions 7

- [Febrile neutropenia](https://durgical.com/en/conditions/febrile-neutropenia/)
- [Tumour lysis syndrome](https://durgical.com/en/conditions/tumour-lysis-syndrome/)
- [Aspergillosis](https://durgical.com/en/conditions/aspergillosis/)
- [Pneumocystis pneumonia (PCP)](https://durgical.com/en/conditions/pneumocystis-pneumonia/)
- [Herpes zoster (shingles)](https://durgical.com/en/conditions/herpes-zoster/)
- [Cytomegalovirus infection](https://durgical.com/en/conditions/cytomegalovirus-infection/)
- [Graft-versus-host disease](https://durgical.com/en/conditions/graft-versus-host-disease/)

## In Pharmacology 11

- [Levofloxacin](https://durgical.com/en/pharmacology/levofloxacin/)
- [Posaconazole](https://durgical.com/en/pharmacology/posaconazole/)
- [Voriconazole](https://durgical.com/en/pharmacology/voriconazole/)
- [Fluconazole](https://durgical.com/en/pharmacology/fluconazole/)
- [Aciclovir](https://durgical.com/en/pharmacology/aciclovir/)
- [Valaciclovir](https://durgical.com/en/pharmacology/valaciclovir/)
- [Entecavir](https://durgical.com/en/pharmacology/entecavir/)
- [Ondansetron](https://durgical.com/en/pharmacology/ondansetron/)
- [Aprepitant](https://durgical.com/en/pharmacology/aprepitant/)
- [Allopurinol](https://durgical.com/en/pharmacology/allopurinol/)
- [Rasburicase](https://durgical.com/en/pharmacology/rasburicase/)

[← All of haematology](https://durgical.com/en/haematology/)

Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.

Sources: [Infection and Neutropenia during Cancer Treatment](https://www.cancer.gov/about-cancer/treatment/side-effects/infection) (National Cancer Institute (NCI), 2026); [Nausea and Vomiting Related to Cancer Treatment (PDQ®)–Health Professional Version](https://www.cancer.gov/about-cancer/treatment/side-effects/nausea/nausea-hp-pdq) (National Cancer Institute (NCI), 2025); [Oral Mucositis](https://www.ncbi.nlm.nih.gov/books/NBK565848/) (StatPearls Publishing (NCBI Bookshelf), 2023); [Information for Patients Who Are Getting Chemotherapy (Preventing Infections in Cancer Patients)](https://www.cdc.gov/cancer-preventing-infections/patients/index.html) (Centers for Disease Control and Prevention, 2025); [Ley 1733 de 2014 (Ley Consuelo Devis Saavedra)](https://www.funcionpublica.gov.co/eva/gestornormativo/norma.php?i=59379) (Función Pública, Gestor Normativo, 2014); [Control integral del cáncer infantil en Colombia: aspectos políticos y normativos (Ley 1388 de 2010)](https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/GCFI/seguimiento-ops-aiepi.pdf) (Ministerio de Salud y Protección Social de Colombia, 2015).

## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake

Representative model, for educational purposes only.

---
Source: https://durgical.com/en/haematology/supportive-care-in-blood-cancers/
License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/haematology/supportive-care-in-blood-cancers/
